SEARCH

SEARCH BY CITATION

References

  • 1
    Brandtzeag P, Haraldsen G, Rugtveit J. Immunopathology of human inflammatory bowel disease. Springer Semin Immunopathol 1997; 18: 55589.
  • 2
    Groux H & Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol Today 1999; 20: 4425.DOI: 10.1016/s0167-5699(99)01510-8
  • 3
    Stallmach A, Strober W, MacDonald TT, Lochs H, Zeitz M. Induction and modulation of gastrointestinal inflammation. Immunol Today 1998; 19: 438438.DOI: 10.1016/s0167-5699(98)01306-1
  • 4
    Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 36575.
  • 5
    Duchmann R, Kaiser L, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102: 44855.
  • 6
    Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263263.
  • 7
    Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 25361.
  • 8
    Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 573344.
  • 9
    Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 94553.
  • 10
    Metchnikoff E. The Prolongation of Life. New York: G.P. Putnom’s & Sons, 1907.
  • 11
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind placebo controlled study. Gastroenterology 2000; 119: 3059.
  • 12
    Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 110714.
  • 13
    Lewis SJ & Freedman AR. The use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 80722.DOI: 10.1046/j.1365-2036.1998.00386.x
  • 14
    Murphy L, Dunne C, Kiely B, et al. In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract. Micro Ecol Health Dis 1999; 11: 14957.
  • 15
    Collins JK, O'Mahony L, Dunne C, et al.Probiotics and man—the host microbe interface. Gastroenterology 1999; 116: G2982G2982.
  • 16
    Dunne C, Murphy L, Flynn S, et al.Probiotics; from myth to reality—Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 1999; 76: 27992.DOI: 10.1023/a:1002065931997
  • 17
    Dunne C, O'Halloran S, O'Mahony L, et al.Epithelial adhesion of probiotic microorganisms in vitro and in vivo. Gastroenterology 1999; 116: G3058G3058.
  • 18
    Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E. Immunity and Probiotics. Immunol Today 1999; 20: 38790.DOI: 10.1016/s0167-5699(99)01448-6
  • 19
    O'Mahony L & Feeney M, et al. Probiotic bacteria and the human immune system In: Buttress J, ed. Functional Foods II: Claims and Evidence. London: Royal Society of Chemistry 2000: 63–70.
  • 20
    Henderson B & Wilson M. Commensal communism and the oral cavity. J Dent Res 1998; 77: 167483.
  • 21
    Rook GA & Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 1136.DOI: 10.1016/s0167-5699(97)01204-8
  • 22
    Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, et al.Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer 1992; 11: 18949.
  • 23
    O'Mahony L. Inflammatory responses; regulation and effects in patients with oesophageal cancer. Thesis. Trinity College Dublin, Ireland, 1998.
  • 24
    Reddy BS, Weisburger JH, Narisawa T, Wynder EL. Colon carcinogenesis in germfree rats with 1,2-dimethylhydrazine and N-methyl-N-nitro-N-nitrosoguanidine. Cancer Res 1974; 74: 236872.
  • 25
    Rowland IR. Toxicology of the colon: role of the intestinal microflora. In: Gibson GR, ed. Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. Boca Raton: CRC Press, 1995: 155–74.
  • 26
    Lidbeck A, Overvik E, Rafter J, et al.Effect of Lactobacillus acidophilus supplements on mutagen excretion in faeces and urine in humans. Micro Ecol Health Dis 1992; 5: 5967.
  • 27
    Hayatsu H & Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993; 73: 1739.
  • 28
    Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventative effect of a lactobacillus preparation on the recurrence of superficial bladder cancer in a double blind trial. The BLP Study Group. Eur Urol 1995; 27: 1049.
  • 29
    Schultz M & Sartor RB. Probiotics and inflammatory bowel disease. Am J Gastroenterology 2000; 95: S1921.
  • 30
    Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 6359.DOI: 10.1016/s0140-6736(98)06343-0
  • 31
    Venturi A, Gionchetti P, Rizzello F, et al.Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 11038.DOI: 10.1046/j.1365-2036.1999.00560.x